Clinical results of preoperative CDDP/5-FU chemotherapy followed by surgery for patients with clinical stage II/III thoracic esophageal cancer.

Yuta Kasagi, Hiroshi Saeki, Kouji Andou, Yukiharu Hiyoshi, Shuhei Ito, Keishi Sugimachi, Yo Ichi Yamashita, Eiji Oki, Hideaki Uchiyama, Hirofumi Kawanaka, Masaru Morita, Tetsuo Ikeda, Yoshihiko Maehara

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The purpose of this study was to clarify the outcomes of preoperative CDDP/5-FU chemotherapy (FP therapy) followed by surgery for patients with clinical Stage II/III thoracic esophageal cancer. Seventeen patients with clinical Stage II/III thoracic esophageal cancer who underwent FP therapy followed by esophagectomy were investigated with regard to the perioperative clinical results and postoperative outcomes. Grade 3 or 4 adverse effects associated with FP therapy were recognized in 2 of the 17 (11.8%) cases, and 16 patients completed 2 cycles of FP therapy (94.1%). Complications after surgery occurred in 7 cases (41.2%). There were 7 patients with postoperative recurrences (41.2%), 6 of whom had clinical Stage III disease. Similarly, 4 out of the 5 patients who died of cancer had clinical Stage III disease. All recurrences and cancer-related deaths were recognized in histological effectiveness of Grade 0/1 cases. Preoperative FP therapy was found to be safe for patients with clinical Stage II/III thoracic esophageal cancer. However, the treatment seemed to be less beneficial for Stage III patients than for Stage II patients, thus suggesting that a more powerful preoperative treatment may be necessary for clinical Stage III patients.

Original languageEnglish
Pages (from-to)523-529
Number of pages7
JournalFukuoka igaku zasshi = Hukuoka acta medica
Volume104
Issue number12
Publication statusPublished - Jan 1 2013

Fingerprint

Esophageal Neoplasms
Fluorouracil
Thorax
Drug Therapy
Therapeutics
Recurrence
Esophagectomy
Neoplasms

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Clinical results of preoperative CDDP/5-FU chemotherapy followed by surgery for patients with clinical stage II/III thoracic esophageal cancer. / Kasagi, Yuta; Saeki, Hiroshi; Andou, Kouji; Hiyoshi, Yukiharu; Ito, Shuhei; Sugimachi, Keishi; Yamashita, Yo Ichi; Oki, Eiji; Uchiyama, Hideaki; Kawanaka, Hirofumi; Morita, Masaru; Ikeda, Tetsuo; Maehara, Yoshihiko.

In: Fukuoka igaku zasshi = Hukuoka acta medica, Vol. 104, No. 12, 01.01.2013, p. 523-529.

Research output: Contribution to journalArticle

Kasagi, Y, Saeki, H, Andou, K, Hiyoshi, Y, Ito, S, Sugimachi, K, Yamashita, YI, Oki, E, Uchiyama, H, Kawanaka, H, Morita, M, Ikeda, T & Maehara, Y 2013, 'Clinical results of preoperative CDDP/5-FU chemotherapy followed by surgery for patients with clinical stage II/III thoracic esophageal cancer.', Fukuoka igaku zasshi = Hukuoka acta medica, vol. 104, no. 12, pp. 523-529.
Kasagi, Yuta ; Saeki, Hiroshi ; Andou, Kouji ; Hiyoshi, Yukiharu ; Ito, Shuhei ; Sugimachi, Keishi ; Yamashita, Yo Ichi ; Oki, Eiji ; Uchiyama, Hideaki ; Kawanaka, Hirofumi ; Morita, Masaru ; Ikeda, Tetsuo ; Maehara, Yoshihiko. / Clinical results of preoperative CDDP/5-FU chemotherapy followed by surgery for patients with clinical stage II/III thoracic esophageal cancer. In: Fukuoka igaku zasshi = Hukuoka acta medica. 2013 ; Vol. 104, No. 12. pp. 523-529.
@article{8410961b9fb3467185053a19cc9f082c,
title = "Clinical results of preoperative CDDP/5-FU chemotherapy followed by surgery for patients with clinical stage II/III thoracic esophageal cancer.",
abstract = "The purpose of this study was to clarify the outcomes of preoperative CDDP/5-FU chemotherapy (FP therapy) followed by surgery for patients with clinical Stage II/III thoracic esophageal cancer. Seventeen patients with clinical Stage II/III thoracic esophageal cancer who underwent FP therapy followed by esophagectomy were investigated with regard to the perioperative clinical results and postoperative outcomes. Grade 3 or 4 adverse effects associated with FP therapy were recognized in 2 of the 17 (11.8{\%}) cases, and 16 patients completed 2 cycles of FP therapy (94.1{\%}). Complications after surgery occurred in 7 cases (41.2{\%}). There were 7 patients with postoperative recurrences (41.2{\%}), 6 of whom had clinical Stage III disease. Similarly, 4 out of the 5 patients who died of cancer had clinical Stage III disease. All recurrences and cancer-related deaths were recognized in histological effectiveness of Grade 0/1 cases. Preoperative FP therapy was found to be safe for patients with clinical Stage II/III thoracic esophageal cancer. However, the treatment seemed to be less beneficial for Stage III patients than for Stage II patients, thus suggesting that a more powerful preoperative treatment may be necessary for clinical Stage III patients.",
author = "Yuta Kasagi and Hiroshi Saeki and Kouji Andou and Yukiharu Hiyoshi and Shuhei Ito and Keishi Sugimachi and Yamashita, {Yo Ichi} and Eiji Oki and Hideaki Uchiyama and Hirofumi Kawanaka and Masaru Morita and Tetsuo Ikeda and Yoshihiko Maehara",
year = "2013",
month = "1",
day = "1",
language = "English",
volume = "104",
pages = "523--529",
journal = "Fukuoka Acta Medica",
issn = "0016-254X",
publisher = "福岡医学会",
number = "12",

}

TY - JOUR

T1 - Clinical results of preoperative CDDP/5-FU chemotherapy followed by surgery for patients with clinical stage II/III thoracic esophageal cancer.

AU - Kasagi, Yuta

AU - Saeki, Hiroshi

AU - Andou, Kouji

AU - Hiyoshi, Yukiharu

AU - Ito, Shuhei

AU - Sugimachi, Keishi

AU - Yamashita, Yo Ichi

AU - Oki, Eiji

AU - Uchiyama, Hideaki

AU - Kawanaka, Hirofumi

AU - Morita, Masaru

AU - Ikeda, Tetsuo

AU - Maehara, Yoshihiko

PY - 2013/1/1

Y1 - 2013/1/1

N2 - The purpose of this study was to clarify the outcomes of preoperative CDDP/5-FU chemotherapy (FP therapy) followed by surgery for patients with clinical Stage II/III thoracic esophageal cancer. Seventeen patients with clinical Stage II/III thoracic esophageal cancer who underwent FP therapy followed by esophagectomy were investigated with regard to the perioperative clinical results and postoperative outcomes. Grade 3 or 4 adverse effects associated with FP therapy were recognized in 2 of the 17 (11.8%) cases, and 16 patients completed 2 cycles of FP therapy (94.1%). Complications after surgery occurred in 7 cases (41.2%). There were 7 patients with postoperative recurrences (41.2%), 6 of whom had clinical Stage III disease. Similarly, 4 out of the 5 patients who died of cancer had clinical Stage III disease. All recurrences and cancer-related deaths were recognized in histological effectiveness of Grade 0/1 cases. Preoperative FP therapy was found to be safe for patients with clinical Stage II/III thoracic esophageal cancer. However, the treatment seemed to be less beneficial for Stage III patients than for Stage II patients, thus suggesting that a more powerful preoperative treatment may be necessary for clinical Stage III patients.

AB - The purpose of this study was to clarify the outcomes of preoperative CDDP/5-FU chemotherapy (FP therapy) followed by surgery for patients with clinical Stage II/III thoracic esophageal cancer. Seventeen patients with clinical Stage II/III thoracic esophageal cancer who underwent FP therapy followed by esophagectomy were investigated with regard to the perioperative clinical results and postoperative outcomes. Grade 3 or 4 adverse effects associated with FP therapy were recognized in 2 of the 17 (11.8%) cases, and 16 patients completed 2 cycles of FP therapy (94.1%). Complications after surgery occurred in 7 cases (41.2%). There were 7 patients with postoperative recurrences (41.2%), 6 of whom had clinical Stage III disease. Similarly, 4 out of the 5 patients who died of cancer had clinical Stage III disease. All recurrences and cancer-related deaths were recognized in histological effectiveness of Grade 0/1 cases. Preoperative FP therapy was found to be safe for patients with clinical Stage II/III thoracic esophageal cancer. However, the treatment seemed to be less beneficial for Stage III patients than for Stage II patients, thus suggesting that a more powerful preoperative treatment may be necessary for clinical Stage III patients.

UR - http://www.scopus.com/inward/record.url?scp=84899997689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899997689&partnerID=8YFLogxK

M3 - Article

C2 - 24693680

AN - SCOPUS:84899997689

VL - 104

SP - 523

EP - 529

JO - Fukuoka Acta Medica

JF - Fukuoka Acta Medica

SN - 0016-254X

IS - 12

ER -